Perrigo announced that it has received final FDA approval for its abbreviated new drug application (ANDA) for clindamycin phosphate and benzoyl peroxide 1.2%/5% topical gel, the generic equivalent of Steifel Laboratories‘ Duac gel.
Duac gel is a combination of clindamycin phosphate and benzoyl peroxide, indicated for the treatment of inflammatory acne vulgaris. Clindamycin phosphate, a lincosamide antibiotic, binds to the 50S ribosomal subunit to inhibit bacterial protein synthesis. Benzoyl peroxide, a lipophilic oxidizing agent, localizes in bacterial and keratinocyte cell membranes to exert bactericidal and keratolytic effects.
Clindamycin phosphate and benzoyl peroxide 1.2%/5% topical gel is available from Perrigo and has commenced shipping.
For more information call (269) 673-8451 or visit www.perrigo.com